High impact information on QUINESTROL

• Compared to controls, patients given bromocriptine had lower prolactin and higher FSH levels during the puerperium whereas the patients given quinestrol had increased prolactin levels and a late fall in FSH levels [1].
• A single 2-mg dose of quinestrol was demonstrated safe and effective for controlling postpartum lactation and for alleviating breast discomfort [2].
• The effects of bromocriptine and quinestrol upon coagulation and fibrinolysis during the puerperium were studied [1].
• Six weeks after delivery elevated levels of factors II and VII and of plasminogen were recorded in women given quinestrol [1].
• The effects of quinestrol and bromocriptine on blood coagulation, serum prolactin and serum FSH levels in puerperal women [1].

Biological context of QUINESTROL

• The persisting changes six weeks after delivery in women who had taken quinestrol might indicate an increased thrombogenic risk when long acting oestrogen preparations are used to inhibit lactation [3].
• The results indicate that once weekly quinestrol is effective in relieving the vasomotor symptoms of the menopause [4].

Anatomical context of QUINESTROL

• Morphometric investigations on endocrine glands. VIII. Karyometry in epithelial cells of thyroid glands during inhibition of lactation by quinestrol [5].

Associations of QUINESTROL with other chemical compounds

• The effects of stilboestrol and quinestrol upon coagulation and fibrinolysis during the puerperium [3].

Gene context of QUINESTROL

• The single oral dose of quinestrol showed efficacy equal to the 2-day regimen of Tace [2].

Analytical, diagnostic and therapeutic context of QUINESTROL

• Quinestrol administered as a single 200 pg-dose significantly augmented the pituitary response to LH-RH 36 hr, 9 days, and although not significantly, also at 24 days after its oral administration [6].
• A specific assay for quinestrol was developed using high-pressure liquid chromatography [7].

References